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BACKGROUND: The role of Notch signalling in human epithelial cancers is of immense interest. In this study, we examine the interplay
between Notch signalling and RhoC, a well-established molecular factor in metastasis. By linking the function of Notch and RhoC, we
further strengthen the notion that there is a pro-oncogenic role of Notch signalling in human cervical cancers.
METHODS: RhoC protein expression in cervical carcinoma cell lines was assessed by western blotting. Using CaSki and SiHa cells
(cervical carcinoma cells lines), we show that RhoC contributes to wound healing, invasion and migration, anoikis resistance, colony
formation, in vitro tube formation and tumour formation. Immunohistochemical studies were carried out to assess the co-expression
of RhoC, pAkt and Notch1 in clinical sections.
RESULTS: An assessment of the changes associated with epithelial-to-mesenchymal transition (EMT) shows that both Notch1 and
RhoC have similar phenotypic contribution to EMT. Rho activity assessment on Notch1 inhibition with DAPT shows decreased RhoC
activity. We further show that constitutively active RhoC rescues the phenotypic effect of Notch1 inactivation, and a comparison of
Notch1 with RhoC expression shows an overlap between the two proteins in the same areas of the tissue.
CONCLUSION: This study has provided evidence to suggest that RhoC is an effector of Notch1 in cervical carcinoma.
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Notch has an important role in cell fate determination, stem cell
maintenance and development (Artavanis-Tsakonas et al, 1999).
Notch1 signalling regulates the maintenance of haematopoietic
stem cells and the development of T cells (Allman et al, 2002). The
Notch receptor is activated on DSL ligand interaction-induced
proteolytic cleavage, leading to the formation of intracellular
Notch1 (ICN). Intracellular Notch1 translocates to the nucleus and
acts as a transcriptional modulator (Honjo, 1996). Activating
mutations have been reported in human T-ALL Notch1 (Weng
et al, 2004); however, limited sequencing of a similar region in
Notch1 alleles of cervical carcinoma suggests the absence of such a
mutation (D Subramanyam and S Krishna, unpublished data).
Dysregulated Notch signalling has been implicated in other
tumours including mammary and cervical cancer (Zagouras
et al, 1995; Daniel et al, 1997; Politi et al, 2004). Cervical
carcinoma, the second most prevalent cancer in women, is
initiated and sustained in part by the presence of high-risk human
papillomavirus oncogene expression (zur Hausen, 2002), and has
an aberrant expression of Notch1, its ligand Jagged1 and down-
stream target Hes1 (Ramdass et al, 2007).
There is a wealth of data suggesting the contribution of ICN to
features of tumour progression, including invasion, epithelial-to-
mesenchymal transition (EMT), metastasis and angiogenesis
(Timmerman et al, 2004; Wang et al, 2006, 2007; Zhang et al,
2008). Notch1 induces anoikis resistance, inhibits p53 activity and
upregulates myc in cervical carcinoma (Rangarajan et al, 2001;
Nair et al, 2003; Klinakis et al, 2006; Subramanyam and Krishna,
2006; Weng et al, 2006) and also inhibits the growth inhibitory
effects of TGF-b during cell growth (Masuda et al, 2005). Our
earlier report suggests that PI3K-mediated EMT in cervical cancer
correlates with Jagged1 expression (Veeraraghavalu et al, 2005).
Although there is data supporting the role of Notch1 in tumour
progression, there is paucity of evidence of factors downstream of
it that regulate these processes. There is emerging evidence that
RhoC regulates features of tumour progression. It regulates
invasion, metastasis, EMT and angiogenesis in various carcinomas
(Sequeira et al, 2008; Wang et al, 2008; Boone et al, 2009),
regulating features similar to Notch1.
RhoC, a small GTPase, belongs to the Rho GTPase family.
Activated Rho GTPases affect actin cytoskeleton dynamics,
transcriptional regulation, cell cycle progression, membrane
trafficking and tumour progression (Vega and Ridley, 2008).
It has also been shown that functional Rho GTPases are required
for Ras-dependent transformation (Qiu et al, 1995). Genomic
comparison of melanoma variants suggested that proteins
regulating actin organisation, such as RhoC, were overexpressed
in highly metastatic melanoma cells (Clark et al, 2000). It has also
been shown to regulate tumour progression in various carcinomas
(Suwa et al, 1998; Clark et al, 2000; Kleer et al, 2002; Kondo et al,
2004). He et al (2008) showed that RhoC-siRNA (short-interfering
RNA) reduced adhesion to Matrigel invasion and migration of
SiHa cells. Studies indicate that a cross-talk exists between RhoC
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sand other signalling molecules such as MAPK and vascular
endothelial growth factor (Vegf). RhoC modulates the MAPK pathway
and increases Vegf, basic fibroblastic growth factor and interleukins 6
and 8 expression (van Golen et al, 2000a, 2002). In another study,
RhoC-siRNA inhibited the growth and invasion of gastric carcinoma
cells through the PI3K/Akt pathway (Sun et al, 2007), and regulated
Pyk2 during tumour metastasis (Iiizumi et al, 2008).
In the absence of reported mutations of the Notch1 locus, as in
leukaemias (Weng et al, 2004), the mechanism of Notch activation
is likely to involve dysregulated ligand expression or altered
patterns of modifiers of the pathway. As phenotypically both
Notch and RhoC signalling molecules regulate similar features
during tumour progression, we explore the possibility of RhoC
being a downstream effector of Notch1. Our results show that
RhoC contributes to invasion, EMT, anoikis resistance, tumour
growth and angiogenesis in cervical carcinoma. We show that
inhibition of Notch1 inactivated the RhoC protein. Using a
combination of genetic and molecular tools, we show that Notch1
inactivation can be rescued by RhoC. Constitutively active RhoC
(caRhoC) can rescue phenotypic changes associated with siRNA-
mediated Notch1 inactivation. Immunohistochemical analysis of
archival tissue suggests a correlation between RhoC and Notch1
expression in human cervical carcinoma tissues. The results imply
that RhoC is an effector of Notch1.
MATERIALS AND METHODS
Cell culture and reagents
CaSki, SiHa and HaCaT cells were cultured in 1  Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% FBS (foetal
bovine serum) and penicillin/streptomycin (100mgml
 1)a t3 7 1C
in 5% CO2 atmosphere. LY294002, GGTI and DAPT were
purchased from Calbiochem (Darmstadt, Germany) and Sigma
(Poole, UK). The following plasmid constructs were used:
pcDNA3-Neo (Invitrogen, Carlsbad, USA), wild-type RhoC
(wtRhoC) and dominant-negative RhoC (dnRhoC) (UMR cDNA
Resource Center), mouse caRhoC (gift from Professor SA
Baldwin), glutathione S-transferase-Rho binding domain (GST-
RBD) (gift from Professor A Ridley) and dn-Akt (Rangarajan et al,
2001). To generate stable clones, transfected cells were treated with
G418 and drug-resistant colonies were selected after RhoC
expression analysis. All transfections were carried out with
Lipofectamine 2000 (Invitrogen), as specified by the manufacturer.
RNA interference
Short-interfering RNAs for Notch1 (ID 16704), RhoC (ID 120897)
and negative control ( ve siRNA) were purchased from Ambion
(Austin, TX, USA). After transfection with 30pmol of siRNA, using
Lipofectamine 2000 (Invitrogen), cells were cultured for 48h
before harvesting for further experiments.
The Notch1 (N1)-shRNA and scrambled shRNA was cloned in
GenScript vector (pRNATin-H1.2/Neo) as a BamHI/HindIII
fragment.
N1-shRNA: (50-GGATCCCACTCGCAGTGGAAGTCATTGATTG
ATATCCGTCAATGACTTCCACTGCGAGTTTTTTTCCAAAAGCTT)
and scramble shRNA: (50-GGATCCCAAGTCACGCTAGTGATAG
AATTTGATATCCGATTCTATCACTAGCGTGACTTTTTTTTCCAA
AAGCTT).
Immunoblotting
Cells washed with cold PBS were incubated with lysis buffer
(20mM Tris–HCl (pH 7.5), 150mM NaCl, 1% NP-40, 1% (v/v)
sodium deoxycholate, 0.1% (w/v) SDS, 50mM NaF, 1mM Na3VO4,
50mgml
 1 PMSF, 1mgml
 1 leupeptin, 1mgml
 1 pepstatin) for
30min on ice, homogenised with a 23-G needle and centrifuged at
14000r.p.m. for 10min at 41C. The lysate was resolved using SDS–
PAGE, blotted and probed using the appropriate antibody. The
primary antibodies used were b-actin (Sigma, clone AC-74),
Notch1 (Sigma, cat. no. N6786), Vegf (Oncogene, Cambridge, MA,
USA, PC-36) and RhoC (Santa Cruz Biotechnology, Inc., CA, USA,
cat. no. sc-26481) at appropriate dilutions.
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed, paraf-
fin-embedded tissue sections. Briefly, the sections were depar-
affinised in xylene, followed by rehydration. After peroxide
quenching and antigen retrieval with sodium citrate, the sections
were incubated overnight at 41C with the following antibodies:
RhoC (Santa Cruz Biotechnology, Inc., cat. no. sc-26481), Notch1
(Santa Cruz Biotechnology, Inc.), Hifa (Santa Cruz Biotechnology,
Inc, cat. no. sc-10790), Vegf (Oncogene, PC-36), Akt (Cell Signaling
Technology, Beverly, MA, USA, clone 736E11) and anti-mouse
CD31 (BD Pharmingen, CA, USA, cat. no. 550274). The sections
were then successively incubated with biotinylated secondary
antibody (Vector Laboratories, Burlingame, CA, USA) and
streptavidin–HRP complex (Vector Laboratories) at room tem-
perature for 40min each. The colour was developed using DAB
(3,30-diaminobenzidine, Sigma, UK). After counterstaining with
haematoxylin, sections were dehydrated, mounted and visualised
under a microscope.
Immunoreactivity was considered significant when the charac-
teristic immunostaining was observed in more than 10% of cells.
The protein expression was classified as mild (þ), moderate
(þþ) and intense (þþþ) on the basis of the intensity of
immunostaining.
Immunofluorescence
Cells grown on coverslips were fixed with 4% (w/v) paraformalde-
hyde (PFA) for 10min at 371C. The cells were quenched with
50mM NH4Cl and permeabilised with 0.1% (v/v) Triton X-100 in
PBS for 5min. After blocking for 1h with 0.2% (v/v) fish skin
gelatin in PBS, the cells were incubated overnight with the
following primary antibodies: anti-fibronectin (Sigma, cat. no.
F6140), Notch1 (Santa Cruz Biotechnology), RhoC (Santa Cruz
Biotechnology, Inc, cat. no. sc-26481) and Plakoglobin (Sigma, cat.
no. P8087), followed by appropriate secondary antibody con-
jugates. Finally, the coverslips were mounted on microscope slides
and imaged using Nikon Inverted Microscope ECLIPSE TE2000-S,
Melville, NY, USA.
Wound-healing assay
Cells cultured to 95% confluence were scratched with a 10-ml
pipette tip. Wounds were photographed at 0h time point, followed
by imaging at later time points, ensuing wound closure using a
Nikon Inverted Microscope ECLIPSE TE2000-S. The nude area was
measured using Image-Pro-Plus (Media Cybernetics, Bethesda,
MD, USA) and percentage wound closure was calculated.
Anoikis assay
Cells were cultured in 1  DMEM in PolyHEMA-coated dishes,
harvested at different time points, fixed with 4% PFA, stained with
Hoechst (1mgml
 1; Sigma) and cell death was estimated by
counting apoptotic nuclei using the Nikon Inverted Microscope
ECLIPSE TE2000-S.
Soft agar colony formation
Cell lines were transfected with indicated plasmids and cultured
for 48h. They were trypsinised and 2 10
5 cells were mixed in
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s0.33% agar in DMEM containing 10% FBS and seeded into 35mm
dishes containing 0.5% agar in DMEM. Cells were grown for 21
days and 200ml of medium was added every third day to the
dishes. At the end of 21 days, 10 random fields were selected and
colonies were counted using a Nikon Inverted Microscope
ECLIPSE TE2000-S.
Invasion and motility assay
For motility and invasion assay, 0.5 10
6 cells in 1  DMEM were
seeded in the top chamber of uncoated or Matrigel-coated
transwell filters with 8mm pores (BD Biosciences, CA, USA). The
bottom chamber contained 1  DMEM with 10% FBS and served
as a chemoattractant. After incubation for 20h at 371C, the cells at
the bottom of the upper chamber were stained with Hoechst
and counted under the Nikon Inverted Microscope ECLIPSE
TE2000-S.
RhoC activity assays
Rho activity assays were performed using the GSTRBD fusion
protein, Rhotekin (for Rho activity) (a gift from Professor Anne
Ridley, UCL, London, UK). Briefly, glutathione sepharose was used
to extract GST-RBD from BL21 cells expressing the GST-RBD
fusion protein. Cultured mammalian cells (pharmacologically
treated and untreated) were lysed using ice-cold lysis buffer
(25mM Hepes (pH 7.5), 150mM NaCl, 10mmoll
 1 MgCl2, 1% NP-
40, 1mM EDTA, 25mM NaF, 1mM NaO4Va and 10% glycerol along
with 2mmoll
 1 phenylmethylsulphonyl fluoride. Lysates were
clarified, protein content was estimated using a BCA assay and an
equal amount of protein was taken for the assay. GST-RBD-
coupled sepharose beads were added to the lysates and incubated
for 1h at 41C to pull down active RhoC. Beads were washed,
denatured, separated by electrophoresis and transferred onto a
nitrocellulose membrane for subsequent analysis by western
blotting.
MTT assay
An equal number of cells were seeded in 96-well plates and
cultured for varying hours. At given time points, the cells were
washed with PBS, and 200ml of MTT (Sigma) working solution
(0.5mgml
 1) was added to the wells and incubated at 371C for 2h.
The media were removed and the converted dye was solubilised in
200ml isopropanol. The absorbance of the converted dye was
measured at a wavelength of 570nm with background subtraction
at 650nm.
Tumour formation in nude mice
Cells were grown in 145-mm-diameter dishes to confluence,
trypsinised, resuspended in 200mlo f1   DMEM and injected
subcutaneously into the flanks of N:NIH-Swiss mice. Each mouse
(aged between 6 and 8 weeks), were injected with 5 10
6 cells.
After 21 days, the mice were killed and the tumour was weighed.
Measurement of tumour vascularity
To measure vascularity, the tumours were processed for immuno-
histochemical analysis by fixing the tumour overnight in 4% PFA
and cryoprotecting in increasing concentrations of sucrose (10–
30%). Tissues were embedded in O.C.T. embedding medium and
4mm sections were collected. The cryosections were immunos-
tained for RhoC and rat anti-mouse CD31 (BD Pharmingen).
Sections were examined by light microscopy under magnifications
 400, and the number of blood vessels from 10 high-power fields
was counted using the Nikon Inverted Microscope ECLIPSE
TE2000-S.
In vitro tube formation assay
A 50-ml Matrigel bed (60%) was prepared in wells of 96-well plates
and was allowed to set for 2h at 371Ci n5 %C O 2 in a humidified
incubator. A total of 7000 human umbilical vascular endothelial
cells were seeded per well in EBM2 media (Cambrex, MD, USA).
The media was supplemented with 50ml of conditioned media for
the assay and tube formation allowed for 16h. The tubes were
imaged using a Nikon Inverted Microscope ECLIPSE TE2000-S (at
200  magnification) and the length of the tube was measured as
the distance between two nodes using Image-Pro-Plus (Media
Cybernetics).
Statistical analysis
Significance of data has been analysed by Student’s t-test. The
correlation of RhoC expression with cervical carcinoma and other
parameters was analysed by the w
2-test.
Figure 1 RhoC drives tumour progression in cervical carcinoma. (A-i) Cell extracts were analysed for RhoC expression in CaSki and SiHa cells. The SiHa
cells show less RhoC expression and activity compared with CaSki cells (n¼2). (A-ii) Graphical presentation of panel Ai. (A-iii) Representative images
showing wtRhoC expression in SiHa cells increased motility in a wound-healing assay (magnification  40). (A-iv) Graphical presentation of panel A-iii
showing faster wound closure by SiHa-wtRhoC compared with SiHa-Neo (Po0.05; n¼4). (A-v) RhoC-siRNA reduced motility (Po0.01) and invasion
(Po0.02) of CaSki cells, –ve siRNA did not alter motility and invasion of CaSki cells. CaSki cells were transfected with siRNA for 48h, cells were trypsinised
and seeded for a transwell migration assay (n¼3). (B-i) Graphical presentation of the effect of dnRhoC resistance to anoikis. Expression of dnRhoC led to
decreased CaSki cell survival (30% non-apoptotic cells; Po0.001) cultured for 7h under anoikis (n¼3). (B-ii) CaSki and SiHa cells formed large colonies
upon wtRhoC overexpression compared with parental cells. Cells were transiently transfected with wtRhoC, cultured for 48h and were seeded for a
clonogenic assay (n¼3). (B-iii) Graphical representation of the effect of dnRhoC on colony formation. The expression of dnRhoC resulted in lesser number
of colonies (16/10 fields; Po0.003) compared with parental CaSki cells (n¼3). (C-i) Overexpression of wtRhoC in SiHa cells resulted in tumours 15-folds
heavier (Po0.02) than SiHa tumours. The black-filled circles indicate the mean tumour weight for each tumour type (n¼6). The empty circles indicate
individual tumour weights (n¼6). (C-ii) Expression of dnRhoC in CaSki cells resulted in smaller tumours, average weight 0.04g (Po0.019) in xenograft
assays in nude mice (n¼3). (D-i) Xenograft cryosections were stained for RhoC and CD31. Representative images suggest increased RhoC and
microvessel-specific CD31 expression in SiHa-wtRhoC tumours. (D-ii) Graphical representation of microvessel density in SiHa-wtRhoC xenografts.
Expression of wtRhoC formed more blood vessels, B12.5 (Po0.009) microvessels per high-power field compared with SiHa tumours. The lumen with
CD31 expression was counted in 10 high-power fields from at least four different sections. (D-iii) Illustrative images representing the effect of RhoC on tube
formation by human umbilical vascular endothelial cells (HUVECs). A total of 7000 cells were seeded in 60% Matrigel (BD Biosciences) and cultured for 16h
with indicated conditioned medium. The distance between the two arrows indicates the length of the tubes (magnification  200). (D-iv) Ectopic
expression of RhoC and its mutant altered in vitro tube formation by HUVECs in Matrigel. Conditioned media from CaSki-dnRhoC and SiHa-wtRhoC,
respectively, decreased and increased tube formation (Po0.001; n¼3). (E) Cervical carcinoma tissue sections immunohistochemically assessed for
expression of RhoC, Hifa and Vegf in serial sections of same tumour sample (scale bar¼30mm). Corresponding normal tissue section images presented as
inset. *Significant difference between the data set.
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sRESULTS
RhoC drives tumour progression in cervical carcinoma
The transition from in situ carcinoma to metastatic tumour in
solid tumours involves motility, invasion, anoikis resistance and
sustained growth. To assess the contribution of RhoC to invasion
and metastasis, we used cervical carcinoma-derived CaSki and
SiHa cells. Figure 1A-i and A-ii shows the expression levels of
RhoC in CaSki and SiHa cells, with higher total RhoC and higher
active RhoC levels in CaSki cells compared with SiHa cells. This
phenotype was complemented in SiHa cells by stably expressing
wtRhoC in stable clones (Supplementary Figure 1A). Dominant-
negative RhoC was also stably expressed in CaSki and SiHa cells.
To assess the contribution of RhoC to motility, we used stable
clones of SiHa cells expressing wtRhoC and dnRhoC in a wound-
healing assay. SiHa-wtRhoC cells closed 80% (Po0.05) of the
wound area as compared with 35% by SiHa Neo cells (expressing
empty vector) in 24h (Figure 1A-iii and iv). The effect of RhoC
depletion on motility and invasion of CaSki cells in a transwell
chamber assay is shown in Figure 1A-v. Compared with control
siRNA ( ve siRNA), RhoC-siRNA treatment resulted in a 75%
(Po0.01) and 45% (Po0.02) decrease in motility and invasion,
respectively, of CaSki cells. The specificity of siRNA activity has
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sbeen shown in Supplementary Figure 1B. Immunofluorescent
analysis of RhoC expression in squamous cervical carcinoma
(SCC) tissues from patients shows the presence of RhoC-
expressing cells in adjoining blood vessels (Supplementary Figure
1C), suggesting that RhoC is involved in metastasis.
Metastatic cells need to resist anoikis in blood vessels to re-grow
as metastases at a distant site. Figure 1B-i shows that a reduction in
RhoC protects cells from anoikis. When cultured for 7h under
anoikis, there were 30% (Po0.001) non-apoptotic CaSki-dnRhoC
cells as compared with 57% non-apoptotic CaSki cells. Similarly,
wtRhoC protected SiHa cells maximally from anoikis for 48h
(Supplementary Figure 1D).
CaSki and SiHa cells transiently expressing wtRhoC formed
bigger colonies (Figure 1B-ii), whereas dnRhoC resulted in a lesser
number of colonies (Figure 1B-iii) in a clonogenic assay. The
number of colonies formed by the CaSki-dnRhoC clone (16
colonies/10 fields) was significantly less compared with CaSki cells
forming 39 colonies/10 fields (Po0.003).
To determine the contribution of RhoC to tumour growth, we
used (5 10
6 cells) stable clones of CaSki and SiHa cells expressing
dnRhoC and wtRhoC, respectively, and generated xenografts in
nude mice over a period of 21 days. As illustrated in Figure 1C-i
and ii, the ectopic expression of RhoC and its mutant altered the
tumour growth properties of CaSki and SiHa cells. SiHa-wtRhoC
cells formed larger tumours (mean weight 353mg; Po0.02)
compared with SiHa cells (16mg). Similarly, CaSki-dnRhoC cells
formed tumours that were significantly smaller (0.016g; Po0.047)
than those formed by CaSki cells (0.054g). Interestingly, the
tumours formed by SiHa-wtRhoC cells were more angiogenic, with
a high microvessel density of 12.5 (Po0.009) microvessels, as
opposed to 1.75 in SiHa tumours (Figure 1D-i and ii; Supplemen-
tary Figure 2A). An immunohistochemical analysis for CD31 and
RhoC on xenograft sections suggests CD31 localisation at the
microvessels. We measured the effect of RhoC on in vitro tube
formation using human umbilical vascular endothelial cells. As
illustrated in Figure 1D-iii and iv, conditioned media derived from
cultures of CaSki, CaSki-dnRhoC, SiHa and SiHa-wtRhoC cells
were used to test the effect. There was significant loss in tube
formation and a resultant reduction in tube length with CaSki-
dnRhoC-derived media (33.66mm; Po0.0001) as compared with
CaSki (41.33mm) media, whereas wtRhoC in SiHa cells enhanced
the tube length (63.45mm; Po0.001) as compared with SiHa cells.
We extended these observations to clinical sections and assessed
the expression of RhoC, Hifa and Vegf in matched cervical
samples. Representative images suggest an expression of RhoC,
Hifa and Vegf in the same area of the tumour (Figure 1E) with
negligible immunodetection in normal cervix tissues suggesting a
co-expression of these molecules. Moreover, a change was
observed in Vegf expression because of RhoC expression.
Supplementary Figure 2B shows that ectopic expressions of
wtRhoC and dnRhoC resulted in elevated and reduced Vegf levels,
respectively, in SiHa and CaSki cells.
Do Notch1 and RhoC regulate similar function during
tumour progression?
Notch1 cooperates with various signalling pathways to promote
tumour progression, including NF-kB, VEGF, TGF-b and p53 (Nair
et al, 2003; Masuda et al, 2005; Wang et al, 2006). As both Notch1
and RhoC are involved in tumour progression and metastasis, we
investigated whether the two signalling molecules regulate similar
functions during cervical tumour progression. Treatment of SiHa
and CaSki cells with DAPT (presenilin-dependent gamma-secre-
tase inhibitor that blocks proteolytic processing of Notch1)
blocked wound healing in CaSki cells but had no effect in SiHa
cells (Supplementary Figure 2C). Furthermore, CaSki cells are
phenotypically similar to most cervical cancers with regard to its
expression of Jagged1, features of activated Notch1 and PI3K
signalling and dependence on Notch1 signalling for growth and
survival (Veeraraghavalu et al, 2005). We thus used CaSki cells to
assess the relationship between RhoC and Notch1.
Depletion of Notch1 and RhoC with siRNA against Notch1 (N1-
siRNA) and RhoC (RhoC-siRNA) inhibited motility and invasion
in CaSki cells (Figure 2A). The motility of CaSki cells reduced to
25% (Po0.01) and 30% (Po0.01) for N1-siRNA- and RhoC-
siRNA-transfected cells. There were 78% (Po0.01) and 66%
(Po0.01) invading RhoC and Notch1 knockout cells compared
with CaSki cells. The effect of N1-siRNA on Notch1 levels has been
shown (Supplementary Figure 2D). Concurrently, in a wound-
healing assay, inhibition of Notch1 with DAPT (40mM), and that
of PI3K with chemical inhibitor LY294002 (LY; 20mM) and
RhoGTPase inhibitor (geranylgeranyl transferase inhibitor
(GGTI); 10mM) for 14h caused reduced wound healing with 24,
52 and 35% (Po0.03) wound closure, respectively, compared with
DMSO-treated cells. Treatment of CaSki cells with the above
inhibitors also resulted in RhoC localisation changes (Supple-
mentary Figure 2E).
As reported earlier, the Notch1 ligand, Jagged1, generates EMT
response in CaSki cells in a Notch1-PI3K-dependent but CBF-
independent manner (Veeraraghavalu et al, 2005). In this study,
CaSki cells transfected with N1-siRNA, RhoC-siRNA and domi-
nant-negative Akt (dn-Akt) were subjected to wound healing for
14h and assessed for fibronectin, plakoglobin and actin stress fibre
organisation. With the progression of wound healing, there was
elevated fibronectin expression and actin stress fibre formation in
untreated CaSki cells at 14h (Figure 2C); however, N1-siRNA,
RhoC-siRNA and dnAkt prevented fibronectin expression and
actin stress fibre formation in cells adjoining the wound site.
Control cells at the 0h time point neither showed fibronectin
expression nor had actin stress fibre formation. Plakoglobin
expression was lost in untreated cells during wound healing at 14h
but contrary to reversal of fibronectin expression, plakoglobin
expression showed no reversal with inhibitors. The data collec-
tively suggest that RhoC phenocopies the effect of Notch1 in EMT
and invasion.
Is RhoC function regulated by Notch1?
The phenotypic similarity between Notch1 and RhoC suggests that
RhoC may be regulated by Notch1. To assess this relationship, we
used GST-RBD (Taylor et al, 2001) to pull down active RhoC-GTP
after treating the cells with the Notch and PI3K inhibitors.
Figure 3A illustrates that the RhoC activation level is decreased
after Notch1 inhibition. The same results were obtained after PI3K
inhibition, indicating that RhoC, which phenocopies the Notch1
effect on EMT, is regulated by the latter. SiHa cells that lack
Jagged1 were used to assess the regulation of RhoC by Notch1. As
shown in Figure 3B-i and -ii, overexpression of wtRhoC and
Jagged1 in SiHa cells formed big (diameter 430mm) colonies
(6 and 13/10 fields, respectively) in a clonogenic assay. Co-expression
of dnRhoC in Jagged1-expressing SiHa cells led to the abolition of
big colonies (Po0.005). We also show that inhibition of PI3K
resulted in the abolition of colonies formed by Jagged1 (Figure 3B-i).
This is in agreement with an earlier report that PI3K mediates
Jagged1-mediated EMT changes (Veeraraghavalu et al, 2005). The
Notch1 expression in HaCaT cells (HaCaT-ACN1) enhances anoikis
resistance through the PKB/Akt pathway (Rangarajan et al, 2001). In
this study, we show that GGTI treatment resulted in reduced anoikis
resistance of HaCaT-ACN1 cells. HaCaT-ACN1 cells showed 33%
non-apoptotic cells at 14h, which reduced to 10% (Po0.002) on
treatment with GGTI (Figure 3B-iii).
Rescue of RNAi-mediated loss-of-function phenotype by
expressing caRhoC, which is refractory to upstream signalling
events, was used to further corroborate RhoC as a downstream
target of Notch1. Ectopic expression of caRhoC in CaSki cells with
depleted Notch1, by N1-siRNA or Notch1 shRNA (N1-shRNA),
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srescued the loss-of-function phenotype of Notch1. As shown in
Figure 3C-i, the N1-siRNA expression in CaSki cells reduced
colonies to 15/10 fields compared with 32 control colonies.
Expectedly, co-expression of caRhoC resulted in significantly
increased colonies (49/10 fields; Po0.0001). Similarly, caRhoC also
rescued the inhibition of the motility and invasion of CaSki cells
because of N1-siRNA expression. Co-expression of caRhoC
resulted in a significant increase in motility (151%; Po0.005)
and invasion (173%; Po0.04) compared with N1-siRNA
(51% motility and 82% invasion)-transfected cells (Figure 3C-ii).
Co-expression of caRhoC in CaSki cells carrying N1-shRNA also
enhanced anoikis resistance (68% non-apoptotic cells; Po0.005)
compared with N1-shRNA cells (40% non-apoptotic cells). The
specificity of N1-shRNA and N1-siRNA has been shown in
Supplementary Figure 2D.
As RhoC inhibition phenocopied the Notch1 and PI3K
inhibitory phenotype, we used CaSki-dnAkt cells (Rangarajan
et al, 2001) to confirm the effect of PI3K inhibition of RhoC
activity in Figure 3A. Expression of dnAkt in CaSki cells caused
decreased motility and enhanced anoikis. As shown in Figure 3D-i,
there was significant reduction in the motility of CaSki-dnAkt cells
(16%; Po0.003) compared with CaSki cells. RhoC activity as
assessed by RBD-GST binding suggested a decreased activity of
RhoC in CaSki-dnAkt cells (Figure 3D-ii). Subsequently, as
expected, overexpression of caRhoC in CaSki-dnAkt cells gener-
ated enhanced anoikis resistance (25% non-apoptotic cells;
Po0.01) compared with 12% non-apoptotic CaSki-dnAkt cells in
14h. These results convincingly position RhoC as a downstream
effector of Notch1 and PI3K signalling in cervical carcinoma cells.
RhoC expression correlates with Notch1 expression in
cervical tumour progression
To further corroborate our findings in a clinical setting, we
examined the expression of RhoC and its relationship with Notch1
in archival cervical carcinoma specimens using immunohisto-
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the expression of Notch1, RhoC and pAkt was assessed in them.
Our results suggest RhoC is strongly expressed in SCC tissues
(Figure 4A). There was significant difference in the extent of
cellular positivity and intensity of RhoC expression across the
grades (Po0.007). Although cytoplasmic expression of RhoC was
observed in all the cases across all grades of tissues, the percentage
of positive cases increased across the tumour grades. Only 5 out of
12 (41%) normal cervical tissues showed RhoC expression
compared with 21 out of 24 (87%) SCC tissues. Of the 87% cases,
65% had mild, 14% had moderate and 8% had intense RhoC
expression.
Correlation of RhoC with Notch1 and pAkt was assessed on
serial sections of SCC tissues and all the molecules were found to
be expressed in the same areas of the various tumour sections
(Figure 4B). Importantly, RhoC expression in the SCC specimens
showed significant correlation with Notch1 expression (Po0.006)
and pAkt expression (Po0.006). Out of 17 SCC specimens, RhoC
was expressed in 14 specimens, whereas Notch1 and pAkt
expression was observed in all 17 specimens. These data
collectively suggest a correlation between RhoC, Notch1 and pAkt.
We thus propose RhoC to be a downstream effector of Notch1 in
cervical tumour progression.
DISCUSSION
Carcinoma progression is a multi-step process engaging various
signalling pathways. There are surmounting evidences elucidating
the contribution of two such pathways including Notch1 and RhoC
to carcinoma progression. Notch1 has been shown to exert
regulations on tumour growth, invasion, metastasis and angiogen-
esis in various carcinomas. Increased expression of RhoC in
metastatic melanoma cells in comparison with the poorly
metastatic counterparts (Clark et al, 2000) was the advent of
studies implicating RhoC in carcinoma progression especially
metastasis.
In accordance with its contribution to motility and invasion of
several cancers (van Golen et al, 2000b; He et al, 2008), our data
show that RhoC contributes to tumour progression by affecting
invasion, anoikis resistance, tumour growth and angiogenesis in
cervical carcinoma cell lines. We show that RhoC drives tumour
progression by regulating invasion, metastasis, tumour growth and
angiogenesis (Figure 1). We find increased vasculature associated
with increased RhoC expression in xenografts grown from SiHa
cells. Immunohistochemical assessment of archival tissue sections
showed expression of RhoC, Vegf and Hifa in the same areas of
tumour sections. Immunofluorescent analysis of paraffin-embedded
SCC tissue sections for RhoC expression showed the presence of
invading cells in the adjoining blood vessels and at the periphery of
the tumour, underlining the importance of RhoC to invasion.
We previously proposed that Notch1 regulates EMT response in
the cervical epithelial cell line, CaSki (Veeraraghavalu et al, 2005). In
this study, we show that RhoC regulates EMT during tumour
progression in a manner similar to Notch1. Inactivation of RhoC
resulted in similar phenotypic changes, as associated with the effect
of Notch and PI3K inhibition of EMT (Figure 2). This finding
parallels that of Hutchison et al (2009), in which RhoC has been
shown to regulate stress fibre formation during EMT. However, we
also show that RhoC regulates fibronectin expression during EMT
changes. Considering that both Notch1 and RhoC regulate similar
features during tumour progression, we explored the possibility of
cross-talk between Notch1 and RhoC. Biochemical assays suggest
that Notch1 regulates RhoC activity in CaSki cells. In this study, we
show that inhibition of Notch and PI3K with pharmacological agents
resulted in reduced RhoC activity in CaSki cells (Figure 3), with no
effect on total RhoC levels. When SiHa cell-overexpressing Jagged1
was complemented with dnRhoC, there was reduced colony
formation. Concomitantly, HaCaT-ACN1 cells (Rangarajan et al,
2001) when treated with GGTI resulted in reduced anoikis-resistant
cells. Consistent with the observation that Notch1 signalling
generates anoikis to resistance in keratinocytes and CaSki cells
(Rangarajan et al, 2001; Veeraraghavalu et al, 2005), we find that
complementation of Notch1-depleted CaSki cells with caRhoC
resulted in increased resistance to anoikis. In parallel, CaSki cells,
expressing Notch1 siRNA or shRNA, when complemented with
caRhoC formed more colonies in a colony formation assay (Figure 3).
Dominant-negative Akt also reduced RhoC activity in CaSki cells.
When CaSki-dnAkt cells were complemented with caRhoC, there was
resultant increase in non-apoptotic cells. However, it should be noted
that RhoC promotes invasion of human melanoma cells in a PI3K/
Akt-dependent manner and promotes metastasis of prostrate cancer
cells by activation of Pyk2, which regulates Akt phosphorylation
(Ruth et al, 2006; Iiizumi et al, 2008).
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Figure 4 RhoC expression correlates with Notch1 expression in cervical tumour progression. Immunodetection of Notch1, RhoC and pAkt in cervical
carcinoma. Immunohistochemical analysis was carried out on paraffin-embedded cervical carcinoma tissue sections using anti-Notch1, anti-RhoC and anti-
pAkt antibodies (magnification  200).
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sUsing immunohistochemical techniques, we show that there is
expression of both Notch1 and RhoC in the same areas of cervical
carcinoma tissue sections with significant correlation while there
was negligible expression of the proteins in the normal cervical
tissue sections (Figure 4). We observed that Notch1 activation and
activated PI3K/Akt regulate RhoC activity in CaSki cells; but we
cannot rule out the role of other signalling pathways regulating
RhoC activity. SiHa cells, for example, lack Jagged1-activated
Notch1 signalling (Veeraraghavalu et al, 2005), yet they exhibit
RhoC activity, which may be regulated by another signalling
pathway. Notch1, which has no reported mutation in solid
tumours, may likely use downstream effectors to execute its
functions in tumour progression. We thus propose RhoC as
downstream effector of Notch1 during tumour progression.
Interestingly, RhoC is not imperative for embryogenesis but is
important for metastasis alone (Hakem et al, 2005), and thus it can
serve as a good therapeutic target. Our data re-iterates the role of
Notch1 in carcinoma progression and places RhoC as its down-
stream target.
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